Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PepGen Inc PEPG

Healthcare Biotechnology
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated... see more

Recent & Breaking News (NDAQ:PEPG)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

Accesswire 1 day ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

Accesswire 8 days ago

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

Business Wire 9 days ago

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

Business Wire November 21, 2024

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Business Wire November 7, 2024

PepGen to Participate in Upcoming Investor Conferences

Business Wire November 4, 2024

PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society

Business Wire October 8, 2024

PepGen Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out

Accesswire October 3, 2024

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into PepGen Inc For Possible Securities Fraud

Accesswire October 2, 2024

PepGen Inc. Is Being Investigated For Securities Related Infractions And The Schall Law Firm Encourages Affected Shareholders To Reach Out

Accesswire October 1, 2024

Investors Are Invited To Join The Schall Law Firm's Inquiry Into PepGen Inc For Possible Securities Fraud

Accesswire September 30, 2024

PepGen Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Encourages Affected Shareholders To Take Part

Accesswire September 29, 2024

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into PepGen Inc For Securities Fraud

Accesswire September 28, 2024

PepGen Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Encourages Affected Shareholders To Lend A Hand

Accesswire September 27, 2024

Investors Are Invited To Take Part In The Schall Law Firm's Inquiry Into PepGen Inc For Possible Securities Fraud

Accesswire September 26, 2024

The Schall Law Firm Is Investigating Whether PepGen Inc. Violated Securities Laws And Affected Stockholders Should Reach Out

Accesswire September 25, 2024

Investors Are Invited To Join The Schall Law Firm's Inquiry Into PepGen Inc For Possible Securities Fraud

Accesswire September 24, 2024

The Schall Law Firm Is Investigating Whether PepGen Inc. Violated Securities Laws And Stockholders With Losses Should Reach Out

Accesswire September 23, 2024

PepGen Inc Is Being Looked Into For Securities Related Infractions And Affected Investors Are Invited To Contact The Schall Law Firm

Accesswire September 22, 2024

The Schall Law Firm Wants Shareholders To Join An Inquiry Into PepGen Inc. For Violating Securities Laws

Accesswire September 21, 2024